← Back to headlines
Grail (GRAL) Receives 'Buy' Rating from Guggenheim on Galleri Potential
Guggenheim has given Grail (GRAL) a 'Buy' rating, citing the potential of its Galleri multi-cancer early detection test.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
